SCHEMBL4710085

SCHEMBL4710085

CN(C)c1nc(N)nc2cc(-c3ccccc3C(F)(F)F)c3c(ccn3CCOC(=O)C(F)(F)F)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 3/20 0.38
GRIN1 Q05586 1/20 0.38
CYP1A2 P05177 3/20 0.35
CYP2D6 P10635 3/20 0.35
CLK4 Q9HAZ1 3/20 0.35
CYP2C9 P11712 1/20 0.35
USP2 O75604 2/20 0.33
CYP3A4 P08684 2/20 0.33
TSHR P16473 2/20 0.33
CYP2C19 P33261 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
PTPN1 P18031 3/20 0.33
ACP1 P24666 1/20 0.33
SCN9A Q15858 2/20 0.31
SCN5A Q14524 1/20 0.31
TLR8 Q9NR97 1/20 0.31
HSD11B1 P28845 1/20 0.30
ALOX15 P16050 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4691391 0.89 SLC2A1 (0.36) GRIN2BGRIN1PTPN1SCN9ASCN5A
Trifluoroacetic Acid SCHEMBL4710084 0.89 GRIN2B (0.38) GRIN2BGRIN1CYP1A2CYP2D6CLK4
SCHEMBL4706331 0.88 CYP1A2 (0.39) GRIN2BGRIN1CYP1A2CYP2D6CLK4
Trifluoroacetic Acid SCHEMBL4707954 0.84 CYP1A2 (0.40) GRIN2BGRIN1CYP1A2CYP2D6CLK4
SCHEMBL4708183 0.84 TLR7 (0.30)
SCHEMBL4708369 0.83 GRIN1 (0.32) GRIN2BGRIN1PTPN1SCN9ASCN5A
SCHEMBL4705957 0.82 CYP1A2 (0.42) CYP1A2CYP2D6CLK4CYP2C9USP2
SCHEMBL4705667 0.82 PTPN1 (0.38) GRIN2BGRIN1CYP1A2CYP2D6CLK4
SCHEMBL4706831 0.81 PTPN1 (0.41) CYP1A2CYP2D6CLK4USP2CYP3A4
SCHEMBL5619987 0.79 PTPN1 (0.39) CYP1A2CYP2D6CLK4USP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226915-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-06-05 US claimed
US-20040229890-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-18 US claimed
EP-1633754-B1 DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-06-11 EP disclosed
US-7226915-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-06-05 US disclosed
US-20040229890-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229890-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, PTPRO, PTPN18 GRIN2B 4339/4885GRIN1 3610/4885CYP1A2 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.